SELECT id, `name`, primary_key, `key`, treemapgroup, name_cn, zacks_table_name, compare_key, compare_display_name from gurufocu_main.financial_definition where termpagedisplay=1 and `key` = 'AdditionalPaidInCapital' RPRX (Royalty Pharma) Additional Paid-In Capital
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (NAS:RPRX) » Definitions » Additional Paid-In Capital

Royalty Pharma (Royalty Pharma) Additional Paid-In Capital

: $4,011 Mil(As of Dec. 2023)
View and export this data going back to 2020. Start your Free Trial

Royalty Pharma's quarterly additional paid-in capital declined from Jun. 2023 ($4,031 Mil) to Sep. 2023 ($4,007 Mil) but then increased from Sep. 2023 ($4,007 Mil) to Dec. 2023 ($4,011 Mil).

Royalty Pharma's annual additional paid-in capital increased from Dec. 2021 ($3,508 Mil) to Dec. 2022 ($3,666 Mil) and increased from Dec. 2022 ($3,666 Mil) to Dec. 2023 ($4,011 Mil).

Royalty Pharma Additional Paid-In Capital Historical Data

The historical data trend for Royalty Pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Premium Member Only Premium Member Only - 2,865.96 3,507.53 3,666.16 4,011.44

Royalty Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Additional Paid-In Capital Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,666.16 3,739.66 4,031.24 4,006.76 4,011.44

Royalty Pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Royalty Pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma (Royalty Pharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (NAS:RPRX) » Definitions » Additional Paid-In Capital
Comparable Companies
LEGN INCY UTHR SRPT TECH BMRN JAZZ ROIV EXEL IONS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
RPRX:Mexico RPD:Germany RPD:Germany
Address
110 East 59th Street, FL 33, New York, NY, USA, 10022
Website
https://www.royaltypharma.com
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Executives
Rory B Riggs director 65 RAILROAD AVE, RIDGEFIELD NJ 07657
Avara Management Ltd 10 percent owner C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
Terrance P. Coyne officer: EVP & CFO C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Pablo G. Legorreta director, officer: CEO, Chairman of the Board 110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
George W. Lloyd officer: EVP, Investments & GC C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Marshall Urist officer: EVP, Research & Investments C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Mario Germano Giuliani director, 10 percent owner C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900
James F. Reddoch officer: EVP, Research & Investments C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022
Nogra Group Sicaf Sif Gg Strategic 10 percent owner C/O NOGRA GROUP SICAF-SIF S.A., 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Nogra Group Sicaf - Sif S.a. 10 percent owner 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227
Catherine M. Engelbert director 110 NORTH CARPENTER STREET, CHICAGO IL 60607
Errol B Desouza director 215 COLLEGE ROAD, PARAMUS NJ 07652
Henry A Fernandez director MSCI INC., 88 PINE STREET, NEW YORK NY 10005
Gregory Norden director 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080